Saturday 17 October 2026
Export TPST’s income statement to Excel — free account
Tempest Therapeutics, Inc.
TPST Healthcare Biotechnology
In the quarter to June 2026, EPS grew 83.6% and free cash flow grew 67.0%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
0.62
0.02
−3.13%
Follow TPST
Tempest Therapeutics, Inc. (TPST) P/E ratio
Tempest Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 2.2× (April 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2017 | 0.0× | — |
| Jun 2017 | 0.0× | — |
| Mar 2017 | 0.0× | — |
| Dec 2016 | 0.0× | — |
| 7 more quarters | Free account |
Against its own ten years
Low 0.0×
High 2.2×
Ten-year median
0.0×
Current reading's percentile
91
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KPRX Kiora Pharmaceuticals, Inc. compare | n/m |
| INTS Intensity Therapeutics Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. compare | n/m |
| PTN Palatin Technologies, Inc. compare | n/m |
| PHIO Phio Pharmaceuticals Corp. compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| TPST Tempest Therapeutics, Inc. | n/m |
| BLRX BioLineRx Ltd. compare | n/m |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)